INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///
ORDER A TEST Log In Contact Us
Hero Background

PROVIDERS /// ONCOLOGY

Creating more options for your patients

Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.

CONTACT us

A comprehensive solution for all of your precision oncology needs

  1. GENOMIC PROFILING

    We deliver a comprehensive view of your patients through our tissue and liquid DNA profiling, somatic and germline testing, tumor-normal matched profiling and RNA sequencing.

  2. ALGORITHMIC TESTS

    We leverage our growing database to create specialized algorithms like Homologous Recombination Deficiency (HRD), Tumor Origin (TO), and DPYD, with more algorithms in development.
  3. CLINICAL TRIAL MATCHING

    We bring just-in-time clinical trial options to patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.
  4. DIGITAL PATHOLOGY & AI

    We are developing AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.
  5. FINANCIAL ASSISTANCE

    We are committed to making our tests accessible for those in financial need. Most applicants who qualify pay no more than $100.
  6. TEMPUS ONE

    The first generative AI-enabled clinical assistant that provides access to patient insights directly at your fingertips.
  7. TEMPUS+

    We provide select participating institutions with access to technical support, customized to meet the unique needs and goals of your cancer center.
  8. EHR INTEGRATION

    We offer easy access to current treatment options and relevant insights through our integration and connectivity capabilities.
  9. CARE PATHWAY SOLUTION

    We empower physicians to deliver the next step in a patient’s care journey with our AI-enabled care pathway intelligence platform.

Streamlining your workflow

One order. One platform. One financial assistance program.

Browse our FAQs

We have established relationships that span from community practices to more than 50% of all academic medical centers in the United States.

Open video in popup image description
Open video in popup image description
Working with the top hospitals in North America

In the rapidly changing world of cancer care and precision medicine, Tempus is the established leader. They provide rapid, accurate results while also continuing to develop innovative strategies to improve patient outcomes. With a focus on both clearly defining actionable mutations and extending treatment options by matching specific patients to specific local and national studies, Tempus is directly changing the patients' lives.

Joseph K Hofmeister, MD, OhioHealth

Working with the top hospitals in North America

Breast cancer care has involved use of biomarkers for years in order to determine appropriate therapy. Genomic information has now been added to the list of crucial biomarkers needed to know how to treat metastatic breast cancer patients with the approval of targeted therapy for BRCA and PIK3CA mutations. Having this information also gives a patient the best opportunity to consider one of numerous biomarker driven clinical trials. These options allow as personalized an approach to treatment as possible and I have no doubt that genomic data will continue to transform the way patients are treated as our field moves forward.

Megan Kruse, MD, Cleveland Clinic

  • 6.5K+

    oncologists rely on Tempus as their precision medicine partner

  • 30K+

    patients have been identified for potential enrollment into clinical trials in our network

  • ~6M

    de-identified research records

  • 20+

    operational countries across North, Central and South America, Europe, the Middle East, and Asia

image description

Our Science

view all publications
  • UPCOMING WEBINAR:

    Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort

    This study published in JAMA Network Open suggests that integration of concurrent tissue and ctDNA testing into the routine management of advanced solid cancers may expand the delivery of molecularly guided therapy and improve patient outcomes.

    Read more
  • UPCOMING WEBINAR:

    Predicting Recurrence Using a Tumor-Uninformed ctDNA Assay Detecting MRD in Patients With Resected Stage II or III Colorectal Cancer: Subset Analysis From the GALAXY Study in CIRCULATE-Japan

    xM is a novel tumor-uninformed assay that demonstrated remarkable performance to detect clinical recurrence at a LMT, and a clinically meaningful correlation with DFS. A larger clinical validation study including longitudinal analysis, correlation with ACT, and outcomes from the GALAXY study is currently underway.

    Read more
  • UPCOMING WEBINAR:

    Real-World Clinical Genomics Study of HR+/HER2- Metastatic Breast Cancers Treated by CDK4/6i plus Endocrine Therapies Revealed a Drug Resistant Tumor Segment Characterized by ER Independence

    Our real-world clinical genomics study identified a comprehensive list of biomarkers associated with resistance to CDK4/6i plus ET and estimated patient prevalence for these markers in the post-treatment setting.

    Read more
  • UPCOMING WEBINAR:

    ESR1 Mutations Drive Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer

    ESR1 mutations are enriched following treatment with CDK4/6i in a cohort of 3,958 patients with ER+/HER2- metastatic breast cancer. Mutations in ESR1 in ER+ breast cancer cells directly promote resistance to CDK4/6i alone or CDK4/6i + antiestrogens in vitro and in vivo.

    Read more
  • UPCOMING WEBINAR:

    Real-world data analysis of genomic profiling-matched targeted therapy outcomes in patients with fusion-positive NSCLC

    This study demonstrates that in a real-world, retrospective cohort, most oncologists utilized CGP to timely treat patients with ESMO-recommended targeted therapy for fusion-positive advanced NSCLC. More importantly, CGP-matched guideline-recommended treatment is associated with improved rwOS.

    Read more
  • UPCOMING WEBINAR:

    ALK fusion detection by RNA next-generation sequencing (NGS) compared to DNA in a large, real-world non-small cell lung cancer (NSCLC) dataset

    This large, real-world dataset demonstrates that RNA NGS increases ALK fusion detection by 18% over DNA alone for patients with advanced NSCLC. Consequently, RNA NGS should be considered for more widespread adoption in the clinic.

    Read more

Featured News and Events

view all news
  • UPCOMING WEBINAR:

    Tempus Expanding Access to its Next-Generation Sequencing Tests as an In-Network Provider for Cigna

    Tempus has signed an agreement for in-network provider status with Cigna Healthcare. The collaboration signifies an important stride in enhancing accessibility to Tempus’ array of molecular profiling tests for Cigna’s extensive network.

    Read more
  • UPCOMING WEBINAR:

    Video: Tempus Product Theater Presentation from the 2023 San Antonio Breast Cancer Symposium

    Hear from Dr. Rebecca Shatsky of UC San Diego Health and Dr. Calvin Chao of Tempus as they explore the latest advancements for enabling precision oncology.

    Watch now
  • UPCOMING WEBINAR:

    Tempus is Now an In-Network Provider for Humana, Expanding Access to its Next-Generation Sequencing Tests

    Tempus has signed agreements for in-network provider status with Humana Inc. Under the agreement, Humana’s over 13 million members will have improved access to Tempus’ portfolio of molecular profiling tests in accordance with their medical policies, expanding precision oncology care throughout the country.

    Read more
  • UPCOMING WEBINAR:

    Tempus Introduces xM MRD to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only

    Adding a novel MRD assay, xM MRD (formerly xM), to Tempus’ comprehensive testing solutions.

    Read more
  • UPCOMING WEBINAR:

    Tempus Announces Medicare Coverage for Tempus xT Across Solid Tumor and Hematologic Malignancies

    Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus xT.

    Read more
  • UPCOMING WEBINAR:

    Video: The evolving landscape in precision oncology: key research findings from the 2023 ASCO Annual Meeting

    Hear from Tempus moderators Dr. Ezra Cohen and Dr. Calvin Chao as they engage in a multi-disciplinary discussion around practice changing approaches to somatic and germline testing with Dr. Ramaswamy Govindan from Siteman Cancer Center and Dr. Cathy Handy Marshall from Johns Hopkins Medicine.

    Watch replay

Validations and Resources

view all resources
  • UPCOMING WEBINAR:

    Tempus xT Validation

    Our Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.

    Read more
  • UPCOMING WEBINAR:

    Tempus xF Validation

    Our non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.

    Read more
  • UPCOMING WEBINAR:

    Standard Requisition Form

    We offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.

    View here

Partnering with Tempus is investing in the future

Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.